Ring Christine 4

What Happened
Christine Ring, Chief Legal Officer of Nurix Therapeutics, was granted equity awards on February 10, 2026: a stock option covering 93,750 shares and restricted stock units (RSUs) covering 42,875 shares. Both items are reported as derivative awards (transaction code A) with an acquisition price of $0.00 (i.e., they are non-cash grants, part of compensation rather than an open-market purchase).

Key Details

• Transaction date: 2026-02-10 (Form filed with accession 0001817199-26-000008 on same date).
• Awards: 93,750-share stock option (derivative) + 42,875 RSUs = 136,625 total awarded. Reported price: $0.00 (grant).
• Vesting for option (F1): vests 1/36 monthly beginning March 10, 2026, through February 9, 2029, subject to continued service.
• RSU details (F2–F4): each RSU equals a contingent right to one share; RSUs vest 1/12 quarterly over three years (first vesting July 30, 2026); RSUs do not expire but vest or are cancelled before vest dates; shares delivered after vesting.
• Shares owned after transaction: not specified in the provided filing excerpt.
• Filing status: appears timely (same-day report).

Context
These are standard compensation grants (an option + RSUs) rather than purchases or sales; options and RSUs vest over time and convert to common stock only upon vesting (RSUs deliver shares; options require exercise). Such awards are routine for senior executives and reflect compensation, not an immediate market buy/sell signal.